PCORI approves $142M to expand PCORnet

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors has approved nearly $142.5 million to support the ongoing development and expansion of its resource for health research known as PCORnet, the National Patient-Centered Clinical Research Network.

The funds include support to add seven health data networks to the collaborative initiative, which is designed to link researchers, patient communities, clinicians and health systems in productive research partnerships that leverage the power of large volumes of health data maintained by the partner networks, according to a release.

PCORI is developing PCORnet to enhance the nation’s capacity to conduct patient-centered health outcomes research more quickly, less expensively and with greater potential impact than is now possible.  

These latest funding awards will support a three-year second phase of development during which several research studies will begin. Specifically, the funding will support 34 individual health data networks that together make up PCORnet, including continued support for 27 networks selected to participate in PCORnet's first phase of development, which began in April 2014. These will be joined by seven new networks that will expand PCORnet's capacity to conduct studies on a wide range of health topics and questions affecting multiple patient populations.

Together, the 34 PCORnet partner networks cover more than 150 conditions and a wide variety of population groups. 

 

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.